Lenacapavir Approval: What to Know When Selecting a PrEP Regimen

Tune in to learn how the recent FDA approval of lenacapavir (LEN) for PreP integrates into the current field of HIV prevention. Listen on the go or follow along with our expert-curated slides. Topics covered include: 

• The current landscape of PrEP
• FDA approval of lenacapavir
• Phase III efficacy and safety data for lenacapavir
• Recommendations and perspectives on the future of PrEP

Presenters:

Colleen F. Kelley, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Co-Director, Emory Center for 
AIDS Research
Associated Dean for Research, 
Emory at Grady
Emory University School of Medicine
Atlanta, Georgia

Raphael J. Landovitz, MD, MSc
Professor of Medicine
Chief, Division of Infectious Diseases
Associate Vice Chair for 
Clinical Research
Department of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Director, UCLA Center for Clinical AIDS Research & Education (CARE)
Director, Center for HIV Identification, Prevention, and Treatment Services (CHIPTS)
Los Angeles, California

Link to full program: 
https://bit.ly/4m8RaOg